Received Oct 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 1 | — | OT |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | OT |
No additional AE; patient received his 1st dose of GARDASIL 4 valent on 11/6/2018 at age 11 years 10 months and did not return for a second dose until 6/23/2025 and received GARDASIL 9 at that time; patient received his 1st dose of GARDASIL 4 valent on 11/6/2018 at age 11 years 10 months and did not return for a second dose until 6/23/2025 and received GARDASIL 9 at that time; patient received his 1st dose of GARDASIL 4 valent on 11/6/2018 at age 11 years 10 months and did not return for a second dose until 6/23/2025 and received GARDASIL 9 at that time; This spontaneous report was received from a pharmacist and refers to an 18-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 06-Nov-2018, the patient was vaccinated with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL) suspension for injection, dose number 1, administered by unknown route (lot # and expiration date were not reported) as prophylaxis. On 23-Jun-2025, the patient received the 2nd dose of with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9) suspension for injection, administered by unknown route (lot # and expiration date were not reported) as prophylaxis (Inappropriate schedule of product administration, Interchange of vaccine products, Wrong product administered). No additional adverse events. At the reporting time, the outcome of the events was unknown.